Skip to content

High Flow Nasal Cannula in the Emergency Department

Use of High-Flow Nasal Cannula for Acute Respiratory Failure in the Emergency Department

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03460119
Acronym
HFNC
Enrollment
43
Registered
2018-03-09
Start date
2015-07-01
Completion date
2017-01-31
Last updated
2018-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure

Keywords

High Flow Nasal Cannula, Emergency department, Respiratory care

Brief summary

The aim of this study was to describe the changes in respiratory rate, heart rate and dyspnea, before and after using HFNC in patients presenting to our emergency department with ARF.

Detailed description

A retrospective cohort study was performed. To all adults presenting to the emergency department who used high flow nasal cannula to treat clinical signs of acute respiratory failure based on the presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min. Demographic variables and clinical and gasometric parameters before and after two hours using HFNC were recorded.

Interventions

The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).

Sponsors

Hospital Italiano de Buenos Aires
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients aged ≥ 18 years * attended between July 1st, 2015 and January 31st , 2017 in the Emergency Department of the Hospital Italiano de Buenos Aires * with clinical signs of acute respiratory failure

Exclusion criteria

\- Pulse oximetry \> 90% breathing room air

Design outcomes

Primary

MeasureTime frameDescription
Heart Rate2 hoursThe closest value of Heart Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
Respiratory Rate2 hoursThe closest value of Respiratory Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
Dyspnea2 hoursThe closest value of Dyspnea (Modified Borg Dyspnea scale) before starting HFNC, and two hours later was collected from the electronic clinical history. The Modified Borg Dyspnea Scale is a rated numerical score used to measure dyspnea. This scale has a minimum value of 0 ( represent no dyspnea) and a maximum value of 10 (worse dyspnea).

Secondary

MeasureTime frameDescription
Delay of HFNC treatmentuntil 24hsThe hours between the admission to HFNC initiation were collected from the electronic clinical history.
Efficacy of HFNC treatment28 daysWhen the patient did not need for escalation to other non-invasive or invasive ventilatory support.
Initial HFNC setting2 hoursThe gas flow rate and the fraction of inspired oxygen at the HFNC initiation of treatment were collected from the electronic clinical history.
Mortality rate at 28 day from ED admission28 daysThe number of patients who died after requiring HFNCO were collected from the electronic clinical history
Palliative Care28 daysConsensus between patient and/or patient´s family and the physician about the care for the terminally ill patient, provided by an organized health service
Failure of HFNC treatment28 daysWhen the patient need non-invasive or invasive ventilatory support or died. The type of ventilatory support post-failure were collected from the electronic clinical history.
Acute respiratory failure etiology3 minutesPresence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min.
Average time of use the HFNCuntil 28 daysThe total hours of use of HFNC were collected from the electronic clinical history.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026